140 related articles for article (PubMed ID: 38300264)
1. ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases.
Li Z; Lu W; Beyett TS; Ficarro SB; Jiang J; Tse J; Kim AY; Marto JA; Che J; Jänne PA; Eck MJ; Zhang T; Gray NS
J Med Chem; 2024 Feb; 67(4):2837-2848. PubMed ID: 38300264
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).
Wolle P; Engel J; Smith S; Goebel L; Hennes E; Lategahn J; Rauh D
J Med Chem; 2019 Jun; 62(11):5541-5546. PubMed ID: 31083997
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
4. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
5. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Pan J; Hao Q; Li Y; Zhou W
Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
[TBL] [Abstract][Full Text] [Related]
8. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
9. Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance.
Moy FJ; Lee A; Gavrin LK; Xu ZB; Sievers A; Kieras E; Stochaj W; Mosyak L; McKew J; Tsao DH
J Med Chem; 2010 Feb; 53(3):1238-49. PubMed ID: 20038108
[TBL] [Abstract][Full Text] [Related]
10. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
11. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
12. Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.
McAulay K; Hoyt EA; Thomas M; Schimpl M; Bodnarchuk MS; Lewis HJ; Barratt D; Bhavsar D; Robinson DM; Deery MJ; Ogg DJ; Bernardes GJL; Ward RA; Waring MJ; Kettle JG
J Am Chem Soc; 2020 Jun; 142(23):10358-10372. PubMed ID: 32412754
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases.
Allen CE; Chow CL; Caldwell JJ; Westwood IM; van Montfort RL; Collins I
Bioorg Med Chem; 2013 Sep; 21(18):5707-24. PubMed ID: 23920481
[TBL] [Abstract][Full Text] [Related]
15. Conformation-tunable ATP-competitive kinase inhibitors.
Agius MP; Ko K; Johnson TK; Phadke S; Soellner MB
Chem Commun (Camb); 2022 Mar; 58(21):3541-3544. PubMed ID: 35195624
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
[TBL] [Abstract][Full Text] [Related]
18. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
[TBL] [Abstract][Full Text] [Related]
19. Chemical genetic strategy for targeting protein kinases based on covalent complementarity.
Garske AL; Peters U; Cortesi AT; Perez JL; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15046-52. PubMed ID: 21852571
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of microtubule affinity-regulating kinase 4 catalytic domain in complex with a pyrazolopyrimidine inhibitor.
Sack JS; Gao M; Kiefer SE; Myers JE; Newitt JA; Wu S; Yan C
Acta Crystallogr F Struct Biol Commun; 2016 Feb; 72(Pt 2):129-34. PubMed ID: 26841763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
